AzTrials
AzTrials

Endometrial CarcinomaNCT06855706

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

A study testing Behavioral Intervention, Best Practice and Biospecimen Collection in people with Endometrial Carcinoma and Recurrent Fallopian Tube Carcinoma, run by Roswell Park Cancer Institute at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II- IV ovarian, primary peritoneal, fallopian tube cancer or endometrial cancer that is newly… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Behavioral Intervention, Best Practice and Biospecimen Collection
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteUnited States
Study dates
4 Jun 2025to 30 Apr 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years old on day of signing informed consent
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Participant must satisfy one of the following conditions:
  • Have a clinically suspected or confirmed diagnosis of stage II-IV ovarian, primary peritoneal, or fallopian tube cancer by clinical presentation and elevated CA-125 and may be awaiting staging surgery or tumor tissue biopsy followed by neoadjuvant chemotherapy. Inclusion of clinically suspected ovarian cancer cases is because we want to capture data starting from the earliest point of the diagnostic pathway and before definitive staging surgery. This allows us to assess the impact of physical activity and the feasibility of wearable device monitoring as patients transition into neoadjuvant chemotherapy and potential surgery
  • Have recurrent ovarian, primary peritoneal, or fallopian tube cancer at any time point of their recurrence, if they meet eligibility criteria (any histology accepted). Inclusion of recurrent ovarian cancer cases is because ovarian cancer often recurs, and understanding physical activity patterns and interventions in patients experiencing recurrence is critical for comprehensive insights. This ensures the study includes the continuum of disease management beyond initial diagnosis
  • Have pre-operative biopsy-proven endometrial cancer (endometrioid, serous, mucinous, or clear cell, poorly differentiated) with plans for surgical resection using a minimally invasive approach or medical management with chemotherapy combination, hormonal treatment or radiation. Inclusion of biopsy-proven endometrial cancer cases but not clinically suspected or recurrent cases is because we are focusing on confirmed, newly diagnosed patients who will undergo surgical resection or medical management
Show all 16Show fewer
  • willing to wear the activity tracking device for at least 70% of their waking hours each day (11 hours/day) throughout the 6-month study period
  • under the care of Roswell Park Comprehensive Cancer Center during the study period, which includes one or more of the following:
  • Receiving cancer treatment at Roswell Park Comprehensive Cancer Center
  • Undergoing surgery at Roswell Park Comprehensive Cancer Center
  • Participating in surveillance visits at Roswell Park Comprehensive Cancer Center
  • Receiving adjuvant treatment at an outside facility but returning to Roswell Park Comprehensive Cancer Center for periodic consultation visits and agreeing to comply with all study procedures, including data sharing from external providers
  • willing to participate in questionnaires and blood and stool collection throughout the study for translational research purposes
  • Participant must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure
  • Have a smartphone with daily internet access that is compatible with the wearable devices and applications used in the study (e.g., Fitbit Sense 2 and CGM applications)
  • NOTE: Patients who are already achieving or exceeding the goal of 150 minutes of physical activity per week are eligible for this study. This inclusion is intentional, as the study aims to evaluate the full spectrum of physical activity levels-both baseline activity and changes over time-and their relationship with clinical outcomes, metabolic measures (e.g., glucose levels), inflammation, and physical function

Who cannot join

  • serious psychiatric illness that is not currently stabilized, including but not limited to:
  • Schizophrenia or other psychotic disorders
  • Bipolar disorder
  • Sever major depressive disorder
  • Severe personality disorders diagnosed by a qualified mental health professional
  • Recent suicide attempt or psychiatric hospitalization within the previous 12 months
Show all 26Show fewer
  • Life expectancy of less than 12 months, as determined by the Investigator based on clinical judgment and available prognostic tools
  • history of other invasive malignancies within the last two years, except for:
  • Non-melanoma skin cancer
  • In situ cervical cancer
  • resting heart rate greater than 120 beats per minute after 10 minutes of seated rest, confirmed on two separate measurements
  • systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 100 mmHg, measured after 10 minutes of seated rest, confirmed on two separate measurements
  • Unstable angina or myocardial infarction within the past 3 months.
  • Unstable Angina: Chest pain at rest or chest pain of increasing frequency, severity, or duration that requires medical attention
  • Myocardial Infarction: Heart attack diagnosed by a medical professional
  • Pregnant or nursing participants will be excluded, as confirmed via urine test during screening procedures.
  • unwilling or unable to follow the protocol requirements, including but not limited to:
  • Cognitive impairment that affects the ability to provide informed consent or comply with study procedures
  • Language barriers without access to adequate translation services
  • Lack of access to necessary technology (e.g., smartphones compatible with study devices)
  • Other factors that would prevent adherence to study protocols
  • Any condition which, in the Investigator's opinion, makes the patient unsuitable for participation in the study or may interfere with the patient's ability to comply with the study requirements or the safety of the patient. Conditions may include, but are not limited to:
  • Severe pulmonary disease
  • Uncontrolled metabolic disorders
  • Other significant medical conditions that pose a risk during increased physical activity
  • Participants who do not provide a valid cell phone number or do not consent to receive SMS messages from Fitabase for motivational and compliance monitoring purposes will be excluded from the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263

    Emese Zsiros, 716-845-8337, emese.zsiros@roswellpark.org

    Emese Zsiros

    Recruiting

Other trials in United States

About this study

Official title: Life on the Go 3: A Randomized Controlled Trial of Automated, Personalized Physical Activity Intervention Using Wearable Devices to Improve Immune Function and Clinical Outcomes in Ovarian and Endometrial Cancer Patients

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity levels and quality of life in patients with stage II- IV ovarian, primary peritoneal, fallopian tube cancer or endometrial cancer that is newly diagnosed. Physical activity is a modifiable risk factor for the prevention and treatment of many diseases. In fact, increased levels of physical activity have been shown to decrease the risk of some cancers as well as increase overall survival in some cancers. Currently, standard of care guidelines include participation in at least 150 minutes of moderate exercise weekly. An automated personalized physical activity intervention may increase physical activity, enhance quality of life, and improve physical function and daily living activities compared to standard recommendations in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer. This trial also evaluates the impact of physical activity on the gut microbiome and immune function. The microbiome is the collection of tiny organisms, like bacteria, that live in and on the body, especially places like the gut. These microorganisms play an important role in health. Information gathered from this study may help understand how the gut microbiome and physical activity influences the immune system in patients with stage II-IV ovarian, primary peritoneal, fallopian tube or newly diagnosed endometrial cancer.

Read the detailed description

PRIMARY OBJECTIVE:

  1. To determine whether an automated, personalized physical activity (PA) intervention using wearable technology increases the proportion of patients with ovarian or endometrial cancer who achieve at least 150 minutes of moderate to vigorous physical activity (MVPA) per week by the end of the first 3 months, compared to standard recommendations.

SECONDARY OBJECTIVES:

  1. To assess whether the physical activity (PA) intervention leads to sustained increases in physical activity levels among patients with ovarian or endometrial cancer by measuring the proportion of participants who maintain at least 150 minutes of moderate to vigorous physical activity (MVPA) per week on average during the last three months of the intervention period (months 4 to 6).

II. To evaluate changes in average weekly active minutes from baseline to 3 months and 6 months between the intervention and control groups.

III. To evaluate the effect of the PA intervention on quality of life among ovarian and endometrial cancer patients, as measured by validated questionnaires.

IV. To assess changes in physical functioning and activities of daily living between the intervention and control groups.

OUTLINE: Patients are randomized to 1 of 2 groups.

ARM I: (PA INTERVENTION): Patients receive personalized PA goals and positive feedback to increase participation in MVPA in 10-15 minute increments up to 150 minutes per week for 12 weeks then sustain participation for an additional 12 weeks (6 months total). Patients also receive ongoing support to maintain or further increase PA levels up to month 6. Patients wear a Fitbit Sense 2 and CGM device continuously throughout the 6 month intervention. Additionally, patients undergo blood sample collection throughout the study.

ARM II (STANDARD PA): Patients receive general PA counseling recommending 150 minutes of activity per week consistent with standard of care at time of enrollment. Patients also wear a Fitbit and continuous glucose monitor (CGM) device for 6 months. Additionally, patients undergo blood sample collection throughout the study.

After completion of study intervention, patients are followed up every 3 months for up to 24 months after enrollment.

Being tested
Behavioral Intervention, Best Practice, Biospecimen Collection, Electronic Health Record Review, Exercise Intervention
Medical subject headings
Endometrial Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Behavioral InterventionBehavioural

    Also called Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy

    Receive personalized PA goals and positive feedback

  • Best PracticeOther

    Also called standard of care, standard therapy

    Receive general PA counseling

  • Biospecimen CollectionProcedure or surgery

    Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection

    Undergo blood sample collection

  • Electronic Health Record ReviewOther

    Ancillary studies

  • Exercise InterventionOther

    Participate in MVPA

  • Medical Device Usage and EvaluationOther

    Wear a Fitbit Sense 2 and CGM device

  • Questionnaire AdministrationOther

    Ancillary studies

  • Supportive CareOther

    Also called Supportive Therapy, Symptom Management, Therapy, Supportive

    Receive ongoing support

Study groups in NCT06855706
Study groupRoleWhat they receive
Arm I (Personalized Physical Activity intervention)ExperimentalPatients receive personalized PA goals and positive feedback to increase participation in MVPA in 10-15 minute increments up to 150 minutes per week for 12 weeks then sustain participation for an additional 12 weeks (6 months total). Patients also receive ongoing support to maintain or further increase PA levels up to month 6. Patients wear a Fitbit Sense 2 and CGM device continuously throughout the 6 month intervention. Additionally, patients undergo blood sample collection throughout the study.
Receives: Behavioral: Behavioral Intervention; Procedure: Biospecimen Collection; Other: Electronic Health Record Review; Other: Exercise Intervention; Other: Medical Device Usage and Evaluation; Other: Questionnaire Administration; Other: Supportive Care
Arm II (Standard PA)Active comparatorPatients receive general PA counseling recommending 150 minutes of activity per week consistent with standard of care at time of enrollment. Patients also wear a Fitbit Sense 2 and CGM device for 6 months. Additionally, patients undergo blood sample collection throughout the study.
Receives: Other: Best Practice; Procedure: Biospecimen Collection; Other: Electronic Health Record Review; Other: Medical Device Usage and Evaluation; Other: Questionnaire Administration

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of participants achieving ≥ 150 minutes of moderate to vigorous physical activity (MVPA) per week

    Will be defined based on Fitbit's activity intensity levels (e.g., minutes spent in moderate and vigorous zones). Fisher's exact test will be used to compare proportions between groups. Will use logistic regression for adjustments for baseline physical activity levels if necessary. A two-sided alpha = 0.05 will be used for statistical significance.

    Measured: At 3 months (weeks 11 and 12)

Secondary outcomes (7)

  1. Proportion of participants maintaining ≥150 minutes of MVPA per week on average

    MVPA will be based on Fitbit's activity intensity levels (e.g., minutes spent in moderate and vigorous zones). Will be compared between groups using the Fisher's exact test.

    Measured: During months 4-6 (weeks 13-24) of the intervention period

  2. Mean change in average weekly active minutes

    Mean changes in average weekly active minutes will be calculated within and between groups. Linear mixed-effects models will be used to assess changes over time between groups and adjusted for baseline activity levels and other covariates.

    Measured: From baseline to 3 and 6 months

  3. Changes in quality of life (QOL) scores -Ovarian Cancer Module

    Will be evaluated using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)- Ovarian (OV)28 . The difference in mean change of QOL scores between the intervention and control groups will be analyzed using analysis of covariance (ANCOVA), adjusting for baseline scores. 28 questions rated on a 4 point rating scale : "Not at all," "A little," "Quite a bit," and "Very much."

    Measured: From baseline to 3 and 6 months

  4. Changes in Quality of life

    36-item Short form Survey (SF-36)Patient-reported outcome measurement for health-related quality of life and activities of daily living scored on a scale of 0 (negative health) to 100 (positive health).

    Measured: From baseline to 3 and 6 months

  5. Change in Quality of Life Score- Endometrial

    EORTC QLQ - Endometrial (EN) 24.he EORTC QLQ-EN24 is a 24-item instrument designed to assess various aspects of treatment-related quality of life specifically in patients undergoing treatment for endometrial cancer.The EORTC QLQ-EN24 uses a 4-point response scale for most items: 1 = not at all, 2 = a little, 3 = quite a bit, and 4 = very much.

    A higher score indicates worse quality of life.

    Measured: From baseline to 3 and 6 months

  6. Functional Status

    Will compare difference in mean change of Lawton Instrumental Activities of Daily Living Scale (IADL) . Statistical analysis will use paired t-tests or non-parametric equivalents if data are not normally distributed. Changes will be analyzed using ANCOVA. Non-parametric tests may be used if data are not normally distributed.

    Measured: From baseline to 3 and 6 months

  7. Functional Status - Katz Index of Activities Daily Living

    Activities of daily living as assessed by the KATz Index. A score of 6 is high whereas a score of 0 is low.

    Measured: From baseline to 3 and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2025
  2. Study start4 Jun 2025
  3. Primary completion30 Apr 2027 (estimated)
  4. Study completion30 Apr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06855706
Sponsor's protocol ID
I 4260824
Other IDs
NCI-2025-00835, I 4260824, P50CA159981
Status last verified
Dec 2025
First submitted
20 Feb 2025
Last updated
6 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Behavioral Intervention, Best Practice and Biospecimen Collection in people with Endometrial Carcinoma and Recurrent Fallopian Tube Carcinoma, run by Roswell Park Cancer Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 16 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of participants achieving ≥ 150 minutes of moderate to vigorous physical activity (MVPA) per week (time frame: At 3 months (weeks 11 and 12)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06855706.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in